Published in Int Urol Nephrol on June 21, 2008
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant (2010) 1.83
Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant (2011) 1.20
Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant (2012) 1.10
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J (2012) 1.00
Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int (2013) 0.96
Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One (2014) 0.94
Magnesium reduces carotid intima-media thickness in a mouse model of pseudoxanthoma elasticum: a novel treatment biomarker. Clin Transl Sci (2012) 0.87
Magnesium and cardiovascular complications of chronic kidney disease. Nat Rev Nephrol (2015) 0.87
Hypomagnesemia and Mortality in Incident Hemodialysis Patients. Am J Kidney Dis (2015) 0.87
Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication. World J Nephrol (2012) 0.86
Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells. Biomed Rep (2015) 0.81
Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients. Clin Kidney J (2014) 0.81
Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: an in vitro and in vivo study. PLoS One (2014) 0.81
Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ Rev (2011) 0.80
Low Magnesium Levels and FGF-23 Dysregulation Predict Mitral Valve Calcification as well as Intima Media Thickness in Predialysis Diabetic Patients. Int J Endocrinol (2015) 0.80
Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk. Clin Exp Nephrol (2015) 0.78
Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner. Exp Ther Med (2015) 0.78
Magnesium in CKD: more than a calcification inhibitor? J Nephrol (2014) 0.77
Lower serum magnesium is associated with vascular calcification in peritoneal dialysis patients: a cross sectional study. BMC Nephrol (2017) 0.75
Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease. ISRN Nephrol (2013) 0.75
Effects of long-term magnesium supplementation on endothelial function and cardiometabolic risk markers: A randomized controlled trial in overweight/obese adults. Sci Rep (2017) 0.75
The Relationship between Magnesium and Endothelial Function in End-Stage Renal Disease Patients on Hemodialysis. Yonsei Med J (2016) 0.75
Prevalence and clinical impact of magnesium disorders in end-stage renal disease: a protocol for a systematic review. Syst Rev (2015) 0.75
Role of Cellular Magnesium in Human Diseases. Austin J Nutr Food Sci (2014) 0.75
Metal Ion-Loaded Nanofibre Matrices for Calcification Inhibition in Polyurethane Implants. J Funct Biomater (2017) 0.75
Impact of magnesium:calcium ratio on calcification of the aortic wall. PLoS One (2017) 0.75
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis (2008) 2.85
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens (Greenwich) (2012) 2.37
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int (2007) 2.17
Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12
The relationship between uric acid and erectile dysfunction in hypertensive subjects. Blood Press (2014) 2.01
Urinary sodium excretion and ambulatory blood pressure findings in patients with hypertension. J Clin Hypertens (Greenwich) (2015) 1.98
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88
Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol (2008) 1.85
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem (2012) 1.67
Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant (2006) 1.53
Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant (2011) 1.50
Can neutrophil-lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? Ren Fail (2014) 1.50
Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant (2007) 1.44
Fatal hyperphosphatemia secondary to a phosphosoda bowel preparation in a geriatric patient with normal renal function. J Clin Gastroenterol (2006) 1.44
Aortic strain, distensibility and elastic modulus are associated with the presence and quantity of coronary calcium. Kardiol Pol (2010) 1.41
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40
The protein science of biosimilars. Nephrol Dial Transplant (2006) 1.36
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif (2009) 1.19
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrol Dial Transplant (2006) 1.16
Parry-Romberg syndrome. Physical, clinical, and imaging features. Neurosciences (Riyadh) (2015) 1.12
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant (2008) 1.11
Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif (2009) 1.10
Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol (2012) 1.09
Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.09
Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res (2007) 1.06
Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant (2004) 1.05
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Hyponatremia associated with sodium valproate in a 22-year-old male. Nephrol Dial Transplant (2007) 1.04
Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol (2008) 1.03
Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation (2006) 1.03
Vascular calcification in chronic kidney disease. Clin Sci (Lond) (2010) 1.03
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int (2004) 1.01
Antimicrobial resistance patterns of urinary tract pathogens and rationale for empirical therapy in Turkish children for the years 2000-2006. Int Urol Nephrol (2008) 1.01
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol (2011) 1.01
Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med (2013) 1.01
Anemia after renal transplantation. Am J Kidney Dis (2006) 1.01
What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension (2013) 1.00
Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant (2010) 0.99
NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther (2013) 0.99
Curcumin protects against ischemia/reperfusion injury in rat kidneys. World J Urol (2008) 0.99
Uric acid and hypertension: cause or effect? Curr Rheumatol Rep (2010) 0.99
Serum vitamin D levels are independently associated with severity of coronary artery disease. J Investig Med (2012) 0.97
Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: a critical approach. J Am Soc Hypertens (2010) 0.96
Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif (2010) 0.96
Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Investig Med (2011) 0.95
Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets (2006) 0.95
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) (2012) 0.95
Nigella sativa protects against ischaemia/reperfusion injury in rat kidneys. Nephrol Dial Transplant (2008) 0.95
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol (2008) 0.95
Erdosteine against acetaminophen induced renal toxicity. Mol Cell Biochem (2006) 0.94
Nigella sativa oil for prevention of chronic cyclosporine nephrotoxicity: an experimental model. Am J Nephrol (2008) 0.94
Arrhythmias in hemodialysis patients. J Nephrol (2009) 0.94
Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant (2013) 0.93
COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant (2012) 0.92
Sirolimus--challenging current perspectives. Ther Drug Monit (2006) 0.92
Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol (2011) 0.92
Sleep disorders: a systematic review of an emerging major clinical issue in renal patients. Int Urol Nephrol (2007) 0.92
Isolated idiopathic ovarian vein thrombosis: a rare case. Int Urogynecol J Pelvic Floor Dysfunct (2004) 0.92
Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol (2010) 0.92
Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol (2009) 0.92
A Rare but serious side effect of Levofloxacin: hypoglycemia in a geriatric patient. Diabetes Care (2006) 0.91
The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health (2005) 0.91
The effect of dietary ginger (Zingiber officinals Rosc) on renal ischemia/reperfusion injury in rat kidneys. Ren Fail (2009) 0.91
The prevalence of chronic kidney disease in the general population in Romania: a study on 60,000 persons. Int Urol Nephrol (2011) 0.91
Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail (2005) 0.91
Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens (2008) 0.90
Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis (2009) 0.90